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PrognosisBackground and purpose: HPV is found in head and neck cancer from all sites with a higher prevalence in
oropharynx cancer (OPC) compared to non-OPC. HPV/p16-status has a signiﬁcant impact on radiotherapy
(RT) outcome in advanced OPC, but less is known about the inﬂuence in non-OPC. We analyzed HPV-
associated p16-expression in a cohort of patients with stage III–IV pharynx and larynx cancer treated
with primary, curatively intended (chemo-)RT, aiming to test the hypothesis that the impact of HPV/
p16 also extends to tumors of non-oropharyngeal origin.
Material and methods: 1294 patients enrolled in previously conducted DAHANCA-trials between 1992
and 2012 were identiﬁed. Tumors were evaluated by p16-immunohistochemistry and classiﬁed as
positive in case of staining in >70% of tumors cells.
Results: Thirty-eight percent (490/1294) of the tumors were p16-positive with a signiﬁcantly higher
frequency in OPC (425/815) than in non-OPC (65/479), p < .0001. In OPC p16-positivity signiﬁcantly
improved loco-regional control (LRC) (adjusted HR [95% CI]: 0.43 [0.32–0.57]), event-free survival
(EFS) (HR 0.44 [0.35–0.56]), and overall survival (OS) (HR: 0.38 [0.29–0.49]), respectively, compared with
p16-negativity. In non-OPC no prognostic impact of p16-status was found for either endpoint: LRC (HR:
1.13 [0.75–1.70]), EFS (HR: 1.06 [0.76–1.47]), and OS (HR: 0.82 [0.59–1.16]).
Conclusions: The independent inﬂuence of HPV-associated p16-expression in advanced OPC treated with
primary RT was conﬁrmed. However, RT-outcome in the group of non-OPC did not differ by tumor
p16-status, indicating that the prognostic impact may be restricted to OPC only.
 2014 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 310–316 This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Squamous cell carcinomas of the head and neck (HNSCCs) have
traditionally been grouped as a cancer entity, mainly based on the
anatomy, common etiology and sensitivity to treatment. HNSCCs
arise from the epithelium of the upper aerodigestive tract and as
such represent a rather heterogeneous group of neoplasias including
carcinomas of the oral cavity, pharynx (oropharynx, nasopharynx
and hypopharynx) and larynx. With the emergence of human
papillomavirus (HPV) as contributing etiological factor in carcino-
genesis of a subgroup of HNSCC [1], the apparent epidemic incidence
increase of HPV-associated HNSCC [2–4] and the potent impact on
treatment sensitivity and prognosis for patientswith HPV-associateddisease, the traditional understanding and therapeutic management
of HNSCC has been more or less revolutionized. The strongest
association with HPV is found in oropharynx cancer (OPC) where
tumours of the tonsils are particularly associated with HPV infection
[5,6] but high-risk HPV, predominantly HPV-16, has been found in
HNSCC from all sites although with a signiﬁcantly higher prevalence
in OPC compared to tumours arising outside the oropharyngeal
region (non-OPC) [7,8].
The Danish Head and Neck Cancer Group (DAHANCA) has a
longstanding tradition for conducting nationwide randomized
trials [9,10] encompassing all eligible Danish HNSCC patients aim-
ing to improve RT-outcome for these patients in general. The use of
HPV-associated p16-expression as stratiﬁcation parameter within
these trials has demonstrated that tumor p16-status is presently
the strongest known independent factor in primary RT of head
and neck cancer [11–17]. Numerous other studies have focused
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conducted randomized trials, concordantly demonstrating a highly
signiﬁcant impact of tumor HPV/p16-status on treatment outcome
[18,19]. These observations are believed to be caused in part by a
higher sensitivity of HPV/p16-positive tumors to RT [20,21] com-
bined with a different and more favorable risk factor proﬁle [22]
and better general health status in the group of patients with
HPV/p16-positive disease. Much less is known about the impact
of HPV/p16-status in non-OPC although a recent paper indicated,
that tumor p16-status also has prognostic value in tumors of
non-oropharyngeal origin [23].
Clinical trials are presently investigating whether de-intensiﬁed
treatment strategies could result in avoidance of excessive toxicity
without compromising outcome for selected patients with HPV/
p16-positive OPC. On the other hand, the European Organisation
for Research and Treatment of Cancer (EORTC) in collaboration
with the DAHANCA has launched a trial (EORTC1219 ROG-HNCG/
DAHANCA29) investigating whether additional intensiﬁcation of
treatment could be beneﬁcial for patients with HPV/p16-negative
HNSCC based on the observed poor outcome for this patient group
[24]. Thus presently there is substantial variation in the treatment
strategies considered for patients with head and neck cancer
dependent of the HPV/p16-status of the tumors. Consequently,
provision of further knowledge regarding outcome for patients
with p16-positive non-OPC is needed in order to secure optimal
and safe treatment for these patients also. Accordingly, in the
present study we analyzed the inﬂuence of HPV-associated p16-
expression in a large cohort of patients with advanced pharynx
and larynx carcinoma treated with primary, curatively intended
RT, aiming to test the hypothesis that the prognostic impact of
HPV/p16 also extends to tumors of non-oropharyngeal origin.Materials and methods
Study population
The study cohort was identiﬁed in the nationwide DAHANCA
database which contains information on all Danish head and neck
cancer patients since 1970. Since a very high proportion of patients
with HPV-associated OPC present with advanced disease stage due
to regional lymphnode involvement at time of diagnosis, we
selected patients with advanced (stage III–IV) pharynx (orophar-
ynx and hypopharynx) and larynx carcinoma to avoid skewness
caused by stage differences between the two groups (OPC vs.
non-OPC). All patients were treated with curatively intended pri-
mary (chemo)radiotherapy within DAHANCA trials from 1992 to
2012 and the impact of tumor p16-status within these individual
trials have been reported previously [11–17]. Due to the speciﬁc
epidemiology (Epstein Barr virus), histology, growth-pattern and
prognosis, nasopharyngeal carcinomas were not included. More-
over, patients with carcinoma of the oral cavity were deliberately
excluded since standard treatment in Denmark of these tumors
often consists of primary surgery followed by postoperative
radiotherapy if indicated. The DAHANCA trials were performed in
accordance with the Helsinki Declaration II, and the patients gave
written informed consent. Both the main studies and the tumor
tissue analyses performed in the present study were approved by
the relevant regional and national ethics committees according
to Danish legislation and regulations.Evaluation of p16 immunohistochemistry
Routine parafﬁn-embedded, formalin-ﬁxed pretreatment tumor
tissues were available from 1294 patients and immunohistochem-
istry (IHC) for p16-expression was performed on whole tumor
sections as previously described [11]. Brieﬂy, parafﬁn sectionswere cut at 5 lm on Superfrost plus charged glass slides (Men-
zel–Glaser), heated at 60 C for 1 h and deparafﬁnized in the
instrument with EZ prep solution (Ventana Medical Systems). Heat
induced antigen retrieval was carried out using Cell Conditioning 1
solution (CC1, Ventana Medical Systems). p16 was detected by
incubating sections with antibody clone JC8 (sc-56330; Santa Cruz
Biotechnology Inc., Santa Cruz, CA) diluted 1:25 for 32 min. JC8 is a
mouse monoclonal immunoglobulin G2a antibody raised against
full-length human p16, particularly suitable for use on formalin-
ﬁxed, parafﬁn-embedded sections. The speciﬁcity was conﬁrmed
by Western blotting [11]. Speciﬁc reactions were detected using
ultraView Universal DAB Detection Kit (Ventana Medical Systems),
and the slides were counterstained with hematoxylin. Sections of
p16-positive cervical carcinoma were used as positive controls.
The scoring and classiﬁcation of the tumors were based in part
on a 70% cutpoint but also in consideration of the typical micro-
scopic appearance of an HPV-related tumor in order to optimise
the correlation with HPV as described and recommended by El-
Naggar et al. for oropharyngeal carcinomas [25]. Up until 2006
the scoring was done retrospectively and a tumor was classiﬁed
as p16-positive in case of strong, diffuse nuclear and cytoplasmatic
staining in more than 70% of carcinoma cells, but tumors display-
ing a conventional keratinizing morphology together with a vari-
able or patchy p16-expression staining pattern were classiﬁed as
p16-negative [26]. Since then p16-IHC has been implemented in
the routine work-up of patients with HNSCC in Denmark and as
such the staining and interpretation of p16-IHC has been per-
formed prospectively by pathologists at the respective oncological
centers.Statistical analysis
The primary endpoint was loco-regional control (LRC) 5 years
after completion of RT and secondary endpoints were event-free
survival (EFS) [27] and overall survival (OS). LRC was deﬁned as
complete and persistent absence of the disease in T-site and regio-
nal lymph nodes (N-site) after radiotherapy. Failure was recorded
in the event of recurrent tumor, or if the primary tumor never com-
pletely disappeared. In the latter situation the tumor was then
assumed to have failed at the time of randomization. Consequently
the endpoint does not include the effect of a successful procedure
with salvage surgery. EFS was deﬁned as loco-regional recurrence
or progression, distant metastasis or death resulting from any
cause and OS was deﬁned as death resulting from any cause.
Regarding LRC patients were followed for at least 5 years and the
survival status of the patients was tracked until the end of 2012.
The v2-test for categorical variables was used to compare
characteristics of p16-positive and negative tumors and OPC vs.
non-OPC, respectively. The actuarial values of the endpoints were
estimated by the Kaplan–Meier method and compared with a log-
rank test. Multivariable hazard ratios (HRs) were estimated by
use of the Cox proportional-hazard method to evaluate prognostic
parameters and treatment with respect to the risk of loco-regional
failure, event-free death and overall death. Additionalmultivariable
analyses were done including an assessment of the interaction
between p16-status and tumor site (OPC vs. non-OPC). All results
were considered signiﬁcant at levels less than 5% (two-sided tests)
and HRs presented with 95% conﬁdence intervals.Results
Table 1 shows patient and tumor characteristics according to
tumor site and p16-status. Sixty-three percent (815) of the tumors
were OPC, and 37% (479) were of non-OPC origin (larynx: 25%
(321) and hypopharynx: 12% (158), respectively). Overall, 38%
Table 1
Patient and tumor characteristics by p16-status and tumor-site.
All patients (n = 1294) Oropharynx (n = 815) Non-oropharynx (n = 479)
p16-positive
(n = 425)
p16-negative
(n = 390)
pa p16-positive
(n = 65)
p16-negative
(n = 414)
pa
No. (%) No. (%) No. (%) No. (%) No. (%)
Tumor site
Oropharynx 815 (63) 425 (100) 390 (100) <.0001b
Larynx 321 (25) 44 (68) 277 (67) <.0001b
Hypopharynx 158 (12) 21 (32) 137 (33)
Age (years)
Median (range) 59 (28–84) 57 (34–83) 58 (28–84) n.s 59 (34–82) 60 (35–83) n.s
Gender
Female 270 (21) 88 (21) 91 (23) n.s 19 (29) 72 (17) .02
Male 1024 (79) 337 (79) 299 (77) 46 (71) 342 (83)
Tumor stage*
T1–2 619 (48) 279 (66) 166 (43) <.0001 27 (42) 147 (36) n.s
T3–4 675 (52) 146 (34) 224 (57) 38 (58) 267 (64)
Nodal status*
N0 235 (18) 19 (4) 60 (15) <.0001 15 (23) 141 (34) n.s
N+ 1059 (82) 406 (96) 330 (85) 50 (77) 273 (66)
Disease stage*
III 434 (34) 101 (24) 132 (34) <.0001 29 (45) 172 (42) n.s
IV 860 (66) 324 (76) 258 (66) 36 (55) 242 (58)
Treatment
5fx/week 380 (29) 71 (17) 118 (30) <.0001 16 (24) 175 (42) .007
6fx/week 914 (71) 354 (83) 272 (70) 49 (76) 239 (58)
No Nimorazole 140 (11) 20 (5) 45 (12) <.0001 4 (6) 71 (17) .00
Nimorazole 1154 (89) 405 (95 345 (88) 61 (94) 343 (83)
No chemotherapy 931 (72) 190 (45) 334 (86) <.0001 56 (86) 351 (85) n.s
Chemotherapy 363 (28) 235 (55) 56 (14) 9 (14) 63 (15)
Abbreviation: n.s, not signiﬁcant.
* International Union of Cancer Research (UICC) 1982 classiﬁcation.
a Chi-square test for comparison between p16-positive and p16-negative tumors.
b Oropharynx vs. non-oropharynx.
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p16-positivity was signiﬁcantly higher in OPC (425/815, 52%) than
in non-OPC (65/479, 14%), p < .0001. The site-speciﬁc distribution
of p16-positivity in non-OPC was as follows: larynx 44/321 (14%)
and hypopharynx 21/158 (13%).
Median age did not differ between groups but in non-OPC
there were signiﬁcantly more women in the p16-positive group
compared to p16-negative non-OPC whereas gender was equally
distributed in OPC. p16-positive OPC were characterized by small
T-size (T1–2) and lymphnode involvement (N+) as opposed to
patients with p16-negative OPC whereas such differences were
not present in non-OPC. The proportion of OPC increased from
52% in the beginning of the recruitment period whereas late in
the period these tumors accounted for approximately 80% of
the patients. The corresponding frequency of p16-positivity
increased from 22% to 70% in the same period. These ﬁndings
reﬂect the demographic shift observed in HNSCC in some parts
of the western world, including Denmark [2] and which in all
probability can be explained by an epidemic increase in the
incidence of HPV-associated p16-positive OPC during the recruit-
ment period. Based on a combination of this demographic shift
and the successive implementation of new treatment strategies
for HNSCC throughout the recruitment time, signiﬁcant differ-
ences in terms of treatment components were observed in the
study cohort, Table 1. Three-hundred and eighty patients were
treated with conventionally fractionated radiotherapy (5fx/week)
with (N = 240) or without (N = 140) Nimorazole, reﬂecting the
use of this treatment strategy in the beginning of the period.
The majority (N = 914) of the patients were treated with moder-
ately accelerated radiotherapy (68 GY/34fx, 6fx/week) concomi-
tant with the hypoxic cell radiosensitizer Nimorazole and aminor proportion of the patients (N = 363) received chemother-
apy (weekly Cisplatinum 40 mg/m2) in addition to moderate
acceleration and Nimorazole. This resulted in signiﬁcant treat-
ment differences between p16-positive and p16-negative tumors
of both oropharyngeal and non-oropharyngeal origin, as can be
seen in Table 1.
At the time of evaluation, 460 patients had failed to achieve per-
sistent loco-regional control within the irradiated volume. Distant
metastasis occurred in 128 patients, 37 in the p16-positive group
of which 24 were isolated distant failures and 91 in the p16-nega-
tive group of which 39 were distant metastasis alone. A total of 426
patients had died with or from the cancer in question, and overall,
666 patients had died.
In the total cohort of 1294 patients, the 5-year actuarial proba-
bility of LRC, EFS and OS was signiﬁcantly better for patients with
p16-positive tumors compared with p16-negativity (LRC: 76% vs.
50%, adjusted HR [95%CI]: 0.51 [0.41–0.65], EFS: 61% vs. 39%,
adjusted HR: 0.50 [0.42–0.60] and OS: 74% vs. 36%, adjusted HR:
0.42 [0.34–0.51], respectively). Similarly, in the group of OPC,
p16-positivity was correlated with a signiﬁcant improvement in
LRC (80% vs. 52%, HR: 0.32 [0.25–0.43], Fig. 1A) EFS (67% vs. 31%,
HR 0.34 [0.27–0.42], Fig. 1C), and OS (80% vs. 37%, HR: 0.26 [0.20–
0.33], Fig. 1E), respectively, compared with p16-negativity. How-
ever, no prognostic impact of p16-status was found in tumors of
non-oropharyngeal origin for either endpoint: LRC (53% vs. 48%,
HR: 0.94 [0.63–1.40], Fig. 1B), EFS (28% vs. 28%, HR: 0.94 [0.68–
1.30], Fig. 1D), and OS (38% vs. 35%, HR: 0.81 [0.56–1.13], Fig. 1F),
respectively. To further investigate whether the impact of p16
would differ by non-OPC sub-site, analysis was also done for larynx
and hypopharynx individually. This revealed that p16-status did
not impact on outcome in neither tumors of the larynx (LRC
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Fig. 1. (A) Actuarial estimated loco-regional tumor control (LRC), (C) event-free survival (EFS) and (E) overall survival (OS) by p16-status in stage III–IV oropharyngeal
carcinomas. (B), (D) and (F) illustrate the actuarial estimated LRC, EFS and OS in the group of advanced non-oropharyngeal carcinoma, respectively.
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[0.51–1.18]) nor hypopharynx (LRC adjusted HR: 0.86 [0.42–1.78],
EFS: 1.09 [0.63–1.89] and OS: 0.74 [0.41–1.31]), respectively.In the ﬁnal Cox proportional hazards analysis adjusting for age
(<60 years vs. >60 years), gender (female vs. male), T-size (T1–2 vs.
T3–4), lymphnode involvement (N0 vs. N+), hypoxic modiﬁcation
314 Impact of HPV/p16 on RT-outcome in advanced oropharynx and non-oropharynx cancer(Nimorazole vs. no Nimorazole), fractionation schedule (6fx/week
vs. 5fx/week) and chemotherapy (chemotherapy vs. no chemother-
apy), p16-status remained a statistical signiﬁcant independent
prognostic factor in the group of patients with OPC (locoregional
failure: HR: 0.43 [0.32–0.57], event-free death: HR: 0.44 [0.35–
0.56] and overall death: HR: 0.38 [0.29–0.49]), whereas no prog-
nostic impact of p16-status could be demonstrated in the group
of patients with non-OPC: (locoregional failure: HR: 1.13 [0.75–
1.70], event-free death: HR: 1.06 [0.76–1.47] and overall death:
HR: 0.82 [0.59–1.16]), Table 2. We did an additional analysis
involving all 1294 patients including an assessment of the interac-
tion between p16-status and tumor site (OPC vs. non-OPC) for all
three endpoints in question. Table 2 shows that p16-positivity
interacted signiﬁcantly (p < 0.0001) with oropharyngeal tumor ori-
gin only. Thus, outcome was signiﬁcantly better for all endpoints in
patients with p16-positive OPC compared with any other patient
group. Moreover, outcomes did not differ signiﬁcantly between
the remaining three groups: p16-neg OPC, p16-pos non-OPC and
p16-neg non-OPC.
Discussion
Knowing that HPV-associated p16-positve HNSCC is predomi-
nantly characterized by oropharyngeal origin and advanced disease
stage, we addressed the question of the potential prognostic impactTable 2
Multivariable analysis for all patients and stratiﬁed by tumor-site.
Endpoint/variable Oropharynx
HR [95% CI]b
Loco-regional failure
Age <60 years vs. >60 years 0.89 [0.68–1.15]
Female vs. male 0.72 [0.52–1.01]
T1–2 vs. T3–4 0.52 [0.40–0.69]
N0 vs. N+ 0.41 [0.27–0.65]
p16pos vs. p16neg 0.43 [0.32–0.57]
Nim vs. no nim 0.78 [0.52–1.15]
6fx/week vs. 5fx/week 0.42 [0.31–0.58]
Chemo vs. no chemo 0.58 [0.39–0.87]
p16pos OPC
p16pos non-OPC
p16neg OPC
p16neg non-OPC
Event-free death
Age <60 years vs. >60 years 0.78 [0.63–0.96]
Female vs. male 0.84 [0.65–1.08]
T1–2 vs. T3–4 0.47 [0.38–0.59]
N0 vs. N+ 0.52 [0.38–0.72]
p16pos vs. p16neg 0.44 [0.35–0.56]
Nim vs. no nim 0.69 [0.50–0.97]
6Fx/week vs. 5Fx/week 0.57 [0.44–0.74]
Chemo vs. no chemo 0.57 [0.42–0.77]
p16pos OPC
p16pos non-OPC
p16neg OPC
p16neg non-OPC
Overall death
Age <60 years vs. >60 years 0.72 [0.58–0.90]
Female vs. male 0.84 [0.64–1.09]
T1–2 vs. T3–4 0.43 [0.34–0.54]
N0 vs. N+ 0.48 [0.35–0.67]
p16pos vs. p16neg 0.38 [0.29–0.49]
Nim vs. no nim 0.78 [0.56–1.09]
6Fx/week vs. 5Fx/week 0.60 [0.46–0.78]
Chemo vs. no chemo 0.36 [0.24–0.53]
p16pos OPC
p16pos non-OPC
p16neg OPC
p16neg non-OPC
Abbreviation: HR, hazard ratio.
a Analysis included an assessment of the interaction between p16-status and tumor-s
b Estimates <1 is in favor of the ﬁrst-mentioned stratum.of p16-status in non-OPC in a selected cohort of patients with stage
III–IV disease. Moreover, we only included patients who were trea-
ted with primary curatively intended (chemo)radiotherapy, delib-
erately excluding patients with oral cavity cancer. Within this
cohort we conﬁrmed the well-known highly signiﬁcant indepen-
dent inﬂuence of tumor p16-expression on loco-regional control
and survival for patients with advanced OPC. In contrast we could
not demonstrate a similar prognostic impact in advanced tumors
of the larynx and hypopharynx where radiotherapy-outcome did
not differ by tumor p16-status. As opposed to our ﬁndings, Chung
et al. recently found signiﬁcant outcome differences within a cohort
of non-OPC where the p16-positive group was found to have
signiﬁcant better outcome than the p16-negative non-OPC. [23].
A possible explanation for the diverging results between the two
studies might be found in the rather distinct differences between
the compositions of the study-cohorts examined. In the RTOG trial
one third of the p16-positive tumors were carcinomas of the oral
cavity treated with primary surgery followed by postoperative che-
moradiation and Cetuximab in the phase II RTOG 0234-trial [28],
whereas our analyses only comprised larynx and pharynx cancer
treated with primary (chemo)radiotherapy.
Tobacco-smoking negatively affects outcome for head and neck
cancer patients treated with radiotherapy [29]. Moreover, it has
been shown that also for p16-positive OPC an accumulated
smoking history of more or less than 10 packyears independentlyNon-oropharynx All patientsa
HR [95% CI]b HR [95% CI]b
1.31 [1.00–1.71] 1.06 [0.88–1.28]
0.51 [0.35–0.76] 0.64 [0.50–0.83]
0.64 [0.47–0.88] 0.57 [0.46–0.70]
0.46 [0.33–0.64] 0.44 [0.34–0.57]
1.13 [0.75–1.70]
0.72 [0.50–1.03] 0.74 [0.57–0.97]
0.59 [0.43–0.82] 0.50 [0.40–0.63]
0.32 [0.17–0.58] 0.47 [0.34–0.65]
0.41 [0.31–0.55]
1.12 [0.75–1.68]
0.95 [0.77–1.18]
1 (Ref)
0.99 [0.80–1.22] 0.86 [0.74–0.99]
0.6 0 [0.45–0.81] 0.76 [0.63–0.91]
0.60 [0.46–0.77] 0.52 [0.44–0.62]
0.47 [0.36–0.61] 0.48 [0.39–0.59]
1.06 [0.76–1.47]
0.95 [0.69–1.29] 0.82 [0.66–1.03]
0.65 [0.50–0.84] 0.60 [0.51–0.73]
0.49 [0.32–0.72] 0.53 [0.42–0.68]
0.41 [0.33–0.51]
1.06 [0.77–1.47]
0.97 [0.82–1.15]
1 (Ref)
0.85 [0.68–1.06] 0.77 [0.66–0.90]
0.65 [0.49–0.88] 0.79 [0.65–0.95]
0.62 [0.48–0.81] 0.50 [0.42–0.60]
0.44 [0.33–0.58] 0.43 [0.35–0.53]
0.82 [0.59–1.16]
1.25 [0.90–1.73] 1.03 [0.81–1.29]
0.69 [0.53–0.90] 0.64 [0.53–0.77]
0.52 [0.34–0.79] 0.42 [0.31–0.55]
0.35 [0.27–0.44]
0.84 [0.60–1.18]
1.00 [0.85–1.21]
1 (Ref)
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group of tumors with mixed aetiology (tobacco and HPV) of impor-
tance for clinical outcome. We did not investigate the impact of
smoking in the present study. However based on a previous study
involving DAHANCA patients [29] we know, that the vast majority
of patients with non-OPC were smokers and as such the possibility
that differences in smoking habits within the group of non-OPC
affect the results seems modest. In the group of OPC, on the other
hand, it cannot be ruled out, that there are some ‘‘never-smokers’’
(<10 packyears) among p16-positive patients that further lift their
outcome and render the difference in prognosis between p16-
positive and p16-negative OPC patients even more pronounced.
The reasons for the apparent site-speciﬁc difference in the prog-
nostic impact of p16-expression observed in the present study
remain unsolved. Observations from preclinical studies indicate
that the enhanced in vitro radiosensitivity of HPV/p16-positive cell
lines derived from OPC is linked to the individual tumor cell [20,21]
and impaired DSB repair capacity of the tumor cells has been sug-
gested to be the predominant mechanism behind the pronounced
radiosensitivity [21]. Whether HPV/p16-positive tumor cells from
non-oropharyngeal sites also possess such enhanced in vitro radio-
sensitivity remains to be elucidated. Moreover, onemight speculate
that the improved radiotherapy-response observed for HPV/p16-
positive OPC may also be associated with the proximity of these
tumors to lymphoid tissue and that interplay between the immune-
system and the viral antigens may contribute to the enhanced
radiosensitivity. Naturally, these hypotheses are far from consoli-
dated and warrant further investigation.
Investigation of the frequency and site-speciﬁc distribution of
p16-expression (diffuse staining in >70% tumor cell) in this large
cohort of advanced carcinoma of the pharynx and larynx revealed
that p16-positivity is signiﬁcantly more frequent in the orophar-
ynx than in the larynx and hypopharynx, and that p16-positivity
at the two last-mentioned sites is a relatively rare event. The use
of p16-IHC as a marker of infection with HPV in OPC is widely used
in clinical trials based on the high concordance between this
method and various other HPV detection methods, including type
speciﬁc HPV-DNA detection by situ hybridization (ISH) [30]. Out-
side oropharynx the correlation is less robust and viral detection
rates show considerable variation which in part can be ascribed
to tumor-site differences but also the use of diverse detection
methods is of importance [7,8,31]. Literature reviews estimate that
the prevalence of HPV in larynx cancer is approximately 24%, based
on PCR-detection methods [7,8], whereas data on the frequency in
hypopharynx is sparse. Using combined HPV-testing with detec-
tion of HPV DNA by PCR and HPV E6/E7 RNA by RT-PCR in 222
HNSCCs, Salazar et al. [32] found a frequency of HPV-positivity of
35% in OPC, 29% in hypopharynx cancer and 5% in laryngeal
tumors. They found signiﬁcant prognostic impact of HPV-status
in OPC, whereas HPV-status appeared to be of no signiﬁcance for
outcome in non-OPC regardless of the applied treatment modality.
Expression of p16 is not restricted to HPV-positive tumors and
using this marker alone as a surrogate of HPV-induced carcinogen-
esis inevitably entails the risk of including some (virally) false-
positive results. We found that the frequency of p16-positivity
was 14% for both larynx and hypopharynx carcinomas which is
in agreement with the ﬁndings of Chung et al. [23] who also inves-
tigated the correlation between p16-IHC and HPV-16 ISH and
found a moderate correlation for tumors of these sites.
The strong and independent prognostic impact of tumor p16-
status on radiotherapy outcome in advanced OPC is indisputable.
In this study we observed, that the number of p16-positive tumors
in the larynx and hypopharynx is relatively rare. Moreover, we did
not ﬁnd any indication that the prognosis for patients with p16-
positive larynx and hypopharynx carcinoma differs from that of
patients with p16-negative OPC and p16-negative non-OPC.Rather, these patient-groups have a signiﬁcantly worse outcome
to primary radiotherapy than patients with p16-positive OPC,
and as such our ﬁndings failed to prove the hypothesis that the
impact of tumor p16-status also extends to non-OPC. Conse-
quently, our data suggests that patients with p16-positive tumors
of the larynx and hypopharynx should be considered candidates
for enhanced, multimodality treatment schedules in line with
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